Companies › United Therapeutics
3 active drug programs in 5 registered trials: 2 Phase 1, 2 Phase 4, 1 Phase 3; Genitourinary, Cardiovascular, Respiratory; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Treprostinil Prostanoid IP receptor agonist | PTGIR | Phase 4 | Pulmonary Arterial Hypertension; Progressive Pulmonary Fibrosis | Nov 2027 |
| 10 GE Xenokidney Porcine-derived kidney with intentional genomic alterations (knockout of GGTA1, CMAH, BHMT | GGTA1, CMAH, BHMT, PERV | Phase 1 | ESRD (End-Stage Renal Disease) | Oct 2028 |
| GGTA1 KO Thymokidney Porcine kidney with GGTA1 gene knockout (xenotransplant) combined with thymic tissue autog | GGTA1 | Phase 1 | ESRD (End-Stage Renal Disease) | Nov 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05943535 | Treprostinil | Phase 3 | Progressive Pulmonary Fibrosis | Respiratory | Nov 2027 |
| NCT05203510 | Treprostinil | Phase 4 | Pulmonary Arterial Hypertension | Cardiovascular | Apr 2028 |
| NCT05203510 | Treprostinil | Phase 4 | Pulmonary Arterial Hypertension | Cardiovascular | Apr 2028 |
| NCT06878560 | 10 GE Xenokidney | Phase 1 | ESRD (End-Stage Renal Disease) | Genitourinary | Oct 2028 |
| NCT07224763 | GGTA1 KO Thymokidney | Phase 1 | ESRD (End-Stage Renal Disease) | Genitourinary | Nov 2029 |
Cash and short-term investments of $2.1bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Xeno Holdings (US), LLC dba ChoironeX Prescient Therapeutics Insmed Johnson & Johnson (Janssen) Liquidia Technologies
Travere Therapeutics Neurocrine Switzerland TolerogenixX Innovacell Iperboreal Pharma Srl
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.